A 69-year-old male patient with cervical discitis received linezolid treatment for two months. The white blood cell count, red blood cell count, hemoglobin, and platelet count of the patient were all below normal ranges. Simultaneously, the blood lactate level increased to 2.6 mmol·L^-1, and he experienced blurred vision and worsening olfactory dysfunction. After discontinuing linezolid, treatment with erythropoietin injections and Diyu Shengbai tablets was initiated. The blood parameters gradually returned to normal, as did the lactate level, and the vision and olfactory impairment of the patient were improved. Using Naranjo’s assessment scale indicated that the adverse drug reaction was "probably relevant" such as pancytopenia, elevated lactate, visual disturbances, and exacerbated olfactory dysfunction, were likely to be due to linezolid. While severe adverse reactions to linezolid typically manifest in isolation, clinicians and pharmacists should remain vigilant for the simultaneous occurrence of multiple adverse reactions. The onset of adverse reactions is associated with the duration of therapy, dosage, and the patient's baseline health. Monitoring of drug levels and relevant parameters during treatment can help in early detection of such adverse reactions.

1.Moellering RC. Linezolid: the first oxazolidinone antimicrobial[J]. Ann Intern Med, 2003, 138(2): 135-142. DOI: 10.7326/0003-4819-138-2-200301210-00015.

2.Kishor K, Dhasmana N, Kamble SS, et al. Linezolid induced adverse drug reactions-an update[J]. Curr Drug Metab, 2015, 16(7): 553-559. DOI: 10.2174/1389200216666151001121004.

3.赵新菊, 王梅. 利奈唑胺致慢性肾脏病患者转氨酶升高、血小板减少、乳酸酸中毒一例并文献复习[J]. 实用药物与临床, 2012, 15(10): 665-668. [Zhao XJ, Wang M. Linezolid induced elevated transaminases,thrombocytopenia and lactic acidosis in a CKD patient: a case report and literature review[J]. Practical Pharmacy and Clinical Remedies, 2012, 15(10): 665-668.] DOI: 10.14053/j.cnki.ppcr.2012.10.020.

4.Xiao B, Deng P, Jin H, et al. Lactic acidosis and thrombocytopenia associated with linezolid therapy: a case report[J]. Am J Case Rep, 2018, 19: 1117-1120. DOI: 10.12659/ajcr.911362.

5.原国家卫生部. 药品不良反应报告和监测管理办法 [EB/OL]. (2011-07-01) [2024-06-04]. https://www.gov.cn/gongbao/content/2011/content_2004739.htm.

6.Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions[J]. Clin Pharmacol Ther, 1981, 30(2): 239-245. DOI: 10.1038/clpt.1981.154.

7.Zhang D, Xu Y, Wang X, et al. Risk factors for thrombocytopenia in patients receiving linezolid therapy: a systematic review and meta-analysis[J]. Eur J Clin Pharmacol, 2023, 79(10): 1303-1014. DOI: 10.1007/s00228-023-03542-z.

8.刘文, 吴侠, 李峰敏, 等. 全血细胞减少的病因诊断及治疗[J]. 中国全科医学, 2011, 14(17): 1961-1963. [Liu  W, Wu X, Li FM, et al. Etiological diagnosis and treatment of pancytopenia[J]. Chinese General Practice, 2011, 14(17): 1961-1963.] DOI: 10.3969/j.issn.1007-9572.2011.17.030.

9.张岩岩, 朱婉, 张静萍, 等. 利奈唑胺致乳酸酸中毒及全血细胞减少1例报道及50例文献复习[J]. 中国感染与化疗杂志, 2017, 17(4): 365-370. [Zhang YY, Zhu W, Zhang JP, et al. Linezolid-induced lactic acidosis and pancytopenia: one case report and literature review of 50 cases[J]. Chinese Journal of Infection and Chemotherapy 2017, 17(4): 365-370.] DOI: 10.16718/j.1009-7708.2017.04.004.

10.Ramesh V, Gattu S, Maqsood M, et al. Linezolid-induced lactic acidosis[J]. BMJ Case Rep, 2024, 17(2): e259335. DOI: 10.1136/bcr-2023-259335.

11.庞昶, 白玉兰. 利奈唑胺致肝功能异常及乳酸酸中毒1例[J]. 中国感染与化疗杂志, 2013, 13(2): 148-149. [Pang C, Bai YL. One case report of linezolid-induced liver damage and lactic acidosis[J]. Chinese Journal of Infection and Chemotherapy, 2013, 13(2): 148-149.] DOI: 10.3969/j.issn.1009-7708.2013.02.017.

12.Im JH, Baek JH, Kwon HY, et al. Incidence and risk factors of linezolid-induced lactic acidosis[J]. Int J Infect Dis, 2015, 31: 47-52. DOI: 10.1016/j.ijid.2014.12.009.

13.Dai Y, Wang Y, Zeng Y, et al. Linezolid and the risk of lactic acidosis: data mining and analysis of the FDA adverse event reporting system[J]. J Clin Pharm Ther, 2020, 45(6): 1422-1426. DOI: 10.1111/jcpt.13245.

14.Wiener M, Guo Y, Patel G, et al. Lactic acidosis after treatment with linezolid[J]. Infection, 2007, 35(4): 278-281. DOI: 10.1007/s15010-007-6302-x.

15.Kronen T, Agrawal A, Reddy P. acute onset lactic acidosis secondary to linezolid[J]. Cureus, 2023, 15(3): e35891. DOI: 10.7759/cureus.35891.

16.张乃菊, 陈天平, 黄睿, 等. 利奈唑胺致乳酸酸中毒研究进展[J]. 中国临床药理学与治疗学, 2020, 25(12): 1408-1413. [Zhang NJ, Chen TP, Huang R, et al. Research progress of linezolid-induced lactic acidosis[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(12): 1408-1413.] DOI: 10.12092/j.issn.1009-2501.2020.12.013.

17.Vazquez JA, Arnold AC, Swanson RN, et al. Safety of long-term use of linezolid: results of an open-label study[J]. Ther Clin Risk Manag, 2016, 12: 1347-1354. DOI: 10.2147/tcrm.s109444.

18.Miller HV, Cao AA, McClelland CM, et al. Linezolid optic neuropathy[J]. Curr Opin Ophthalmol, 2023, 34(6): 481-486. DOI: 10.1097/icu.0000000000000995.

19.De Vriese AS, Coster RV, Smet J, et al. Linezolid-induced inhibition of mitochondrial protein synthesis[J]. Clin Infect Dis, 2006, 42(8): 1111-1117. DOI: 10.1086/501356.

20.武丹威, 李锦, 李静, 等. 利奈唑胺致视神经炎的文献分析[J]. 医药导报, 2023, 42(2): 262-267. [Wu DW, Li  J, Li J, et al. Literature case analysis of linezolid-induced optic neuritis[J]. Herald of Medicine, 2023, 42(2): 262-267.] DOI: 10.3870/j.issn.1004-0781.2023.02.023.

21.Grohmann SM, Berman A, Grassi MA. Linezolid-induced photoreceptor dysfunction masquerading as autoimmune retinopathy[J]. Doc Ophthalmol, 2020, 140(1): 77-82. DOI: 10.1007/s10633-019-09725-3.

22.Jaspard M, Butel N, El Helali N, et al. Linezolid-associated neurologic adverse events in patients with multidrug-resistant tuberculosis, France[J]. Emerg Infect Dis, 2020, 26(8): 1792-1800. DOI: 10.3201/eid2608.191499.

23.Chaitali P, Suresh R. Comment on Linezolid induced optic neuropathy[J]. Indian J Ophthalmol, 2015, 63(1): 75-76. DOI: 10.4103/0301-4738.151484.

24.Rao GG, Konicki R, Cattaneo D, et al. Therapeutic drug monitoring can improve linezolid dosing regimens in current clinical practice: a review of linezolid pharmacokinetics and pharmacodynamics[J]. Ther Drug Monit, 2020, 42(1): 83-92. DOI: 10.1097/ftd.0000000000000710.

25.自雪梅, 张峻, 何瑾. 利奈唑胺血药浓度影响因素的研究进展[J]. 中国合理用药探索, 2023, 20(2): 66-70. [Bai XM, Zhang J, He J. Influencing factors of linezolid plasma concentration: an review[J]. Chinese Joural of Rational Drug Use, 2023, 20(2): 66-70.] DOI: 10.3969/j.issn.2096-3327.2023.02.007.

26.李娟, 张峻, 王晶晶, 等. 利奈唑胺血药浓度监测结果及影响因素分析[J]. 中国药师, 2022, 25(8): 1406-1409. [Li J, Zhang J, Wang JJ, et al. Analysis of plasma concentration monitoring results and influencing factors associated with linezolid[J]. China Pharmacist, 2022, 25(8): 1406-1409.] DOI: 10.19962/j.cnki.issn1008-049X.2022.08.019.

27.Lin B, Hu Y, Xu P, et al. Expert consensus statement on therapeutic drug monitoring and individualization of linezolid[J]. Front Public Health, 2022, 10: 967311. DOI: 10.3389/fpubh.2022.967311.

28.Kulkarni K, Del Priore LV. Linezolid induced toxic optic neuropathy[J]. Br J Ophthalmol, 2005, 89(12): 1664-1665. DOI: 10.1136/bjo.2005.074237.

29.Keutzer L, Mockeliunas L, Sturkenboom MGG. Derivation and clinical utility of safety targets for linezolid-related adverse events in drug-resistant tuberculosis treatment[J]. Pharmaceuticals (Basel), 2023, 16(11): 1575. DOI: 10.3390/ph16111575.

30.叶雪梅, 陈裕. 利奈唑胺血药浓度与血液毒性相关性的回顾性分析[J]. 药物流行病学杂志, 2020, 29(6): 391-394. [Ye XM, Chen Y. Correlation analysis of linezolid concentration and blood toxicity[J]. Chinese Journal of Pharmacoepidemiology, 2020, 29(06): 391-394.] DOI: 10.19960/j.cnki.issn1005-0698.2020.06.004.